Pertussis Vaccine Sales

Pertussis Vaccine Sales Market Outlook

The global Pertussis Vaccine market is projected to reach USD 3.5 billion by the year 2035, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025-2035. This growth is primarily driven by an increasing incidence of whooping cough, particularly in under-vaccinated populations, along with rising awareness among healthcare professionals and parents about the importance of vaccinating infants and children. Moreover, advancements in vaccine technology, coupled with government initiatives to promote vaccination, are expected to contribute significantly to the expansion of this market. The focus on preventive healthcare and the implementation of strict immunization schedules worldwide further underscore the increasing demand for pertussis vaccines. In addition, the rise in healthcare expenditure and the increasing number of vaccination programs are anticipated to bolster market growth as well.

Growth Factor of the Market

The Pertussis Vaccine market is significantly influenced by several growth factors, including the globalization of disease prevention initiatives. Governments and health organizations are increasingly prioritizing immunization programs to eliminate vaccine-preventable diseases, leading to heightened efforts to distribute pertussis vaccines. The rising number of outbreaks in various regions is also driving the demand for vaccination, as public health authorities strive to mitigate the spread of whooping cough. Additionally, the growth in healthcare infrastructure and increased access to healthcare services in developing countries is contributing to the expansion of the market. The growing awareness among parents regarding the importance of early vaccination, especially for infants, is fostering a larger uptake of pertussis vaccines. Furthermore, collaborative efforts among pharmaceutical companies, healthcare providers, and governments to develop and circulate more effective vaccines are propelling market growth.

Key Highlights of the Market

• The market is projected to grow at a CAGR of 7.5% from 2025 to 2035.
• Government initiatives promoting vaccination are leading to increased uptake.
• Technological advancements in vaccine development are enhancing effectiveness.
• Awareness campaigns about the dangers of whooping cough are boosting demand.
• The rising incidence of pertussis in under-vaccinated populations is a key driver.

By Product Type

Whole-cell Pertussis Vaccine:

The Whole-cell Pertussis Vaccine is a traditional form of vaccination that utilizes the inactivated form of the Bordetella pertussis bacteria. This type of vaccine is known for producing a strong immune response and is usually given as part of combination vaccines, such as DTP (Diphtheria, Tetanus, and Pertussis). Despite its effectiveness, whole-cell vaccines can lead to mild to moderate side effects, including fever and irritability in some cases. This has led to a shift towards acellular vaccines in many regions. However, the whole-cell vaccine continues to be favored in certain countries due to its cost-effectiveness and strong public health impact, particularly in areas experiencing outbreaks of whooping cough. The market for this product type is expected to remain robust owing to its longstanding history and proven efficacy, even as newer formulations become available.

Acellular Pertussis Vaccine:

The Acellular Pertussis Vaccine represents a more modern approach to immunization against whooping cough. This vaccine is made using purified components of the Bordetella pertussis bacteria, which have been shown to elicit a strong immune response while minimizing the likelihood of adverse reactions. Consequently, acellular vaccines have become the preferred choice in many developed countries, especially for infants and children. The increasing demand for safer vaccination options is expected to drive the growth of this product type. Moreover, the acellular vaccine is often combined with other vaccines in multi-dose formulations, allowing for easier administration and compliance with vaccination schedules. As new research validates the effectiveness of acellular vaccines in preventing pertussis, their market share is projected to expand significantly over the next several years.

By Age Group

Infants:

Infants are the primary target group for pertussis vaccination, as they are at the highest risk of severe complications from whooping cough. The vaccination schedule typically starts at two months of age, with a series of doses administered during the early years of life. This early immunization is crucial, given the vulnerability of infants to respiratory infections and the potentially life-threatening nature of pertussis. Increased awareness among parents about the importance of timely vaccinations, coupled with recommendations from pediatricians and public health agencies, has led to a rising demand for infant vaccination. Furthermore, initiatives promoting maternal vaccination during pregnancy help provide passive immunity to newborns, thereby enhancing protection against pertussis during the critical early months of life.

Children:

Vaccination for children against pertussis is essential to provide ongoing immunity as they grow older. The primary series of vaccinations is generally followed by booster doses during childhood, typically around the ages of 4-6 years and again at 11-12 years. This scheduling is crucial to maintain immunity, as the effectiveness of the vaccine may diminish over time. Recent trends indicate a growing focus on ensuring that children complete their vaccination schedules, driven by educational programs that emphasize the importance of vaccinations in preventing communicable diseases. As outbreaks of whooping cough continue to occur, particularly in school-aged children, the significance of maintaining vaccination coverage in this age group is becoming more pronounced, presenting opportunities for market growth.

Adults:

Although pertussis vaccination is primarily associated with infants and children, there is a growing recognition of the need for adult vaccination as well. Adults can become susceptible to whooping cough, particularly if they have not received a booster in the last decade. The Tdap (tetanus, diphtheria, and pertussis) vaccine is recommended for adults, especially those who are caregivers for infants, as this helps to create a cocoon of immunity around the most vulnerable populations. The increasing awareness of the importance of adult vaccination is expected to drive the market for this age group. Moreover, public health campaigns encouraging adults to receive the Tdap booster have resulted in increased uptake, indicating a positive trend towards the recognition of adult immunization as a critical component of public health strategy.

By Distribution Channel

Hospitals:

Hospitals serve as a primary distribution channel for pertussis vaccines due to their comprehensive healthcare services and access to patients. The availability of a range of healthcare professionals, including pediatricians and infectious disease specialists, allows for effective patient education and vaccination administration. Hospitals generally have the infrastructure to handle various formulations of vaccines and ensure proper storage and handling. The rising number of hospital-based vaccination programs and immunization clinics is contributing to the growth of this distribution channel. Furthermore, hospitals often collaborate with health departments and pharmaceutical companies to facilitate outreach programs aimed at increasing vaccination rates among high-risk populations, further solidifying their role in the pertussis vaccine market.

Clinics:

Clinics are another significant distribution channel for pertussis vaccines, often providing more localized and accessible vaccination services compared to hospitals. Many clinics are specialized in pediatric care and are equipped to administer vaccines according to recommended schedules. The convenience of clinics, particularly for busy parents, encourages higher vaccination rates among infants and young children. Additionally, community health clinics often engage in outreach efforts to educate the public about the importance of vaccinations, helping to alleviate concerns and misinformation regarding vaccine safety. As a result, clinics play a crucial role in increasing overall vaccination coverage, thereby supporting market growth for pertussis vaccines.

Retail Pharmacies:

In recent years, retail pharmacies have emerged as a vital distribution channel for pertussis vaccines, offering increased convenience for patients seeking vaccination without the need for a doctor's appointment. Many pharmacies have established partnerships with healthcare providers to offer immunization services, often employing trained pharmacists to administer vaccines. This accessibility is particularly advantageous for adults seeking Tdap boosters, as it allows for walk-in vaccination options. The expansion of pharmacy-based immunization programs, combined with promotional campaigns to raise awareness about the importance of vaccination, is expected to further boost the presence of retail pharmacies in the pertussis vaccine market. Additionally, the rise of vaccine education initiatives within pharmacies helps to reinforce the role of this channel in promoting public health.

By End User

Pediatric Vaccination Centers:

Pediatric vaccination centers are specialized facilities focused on providing immunization services for children, making them a fundamental end user in the pertussis vaccine market. These centers are typically equipped with trained healthcare professionals who understand the specific needs and concerns of parents regarding childhood vaccinations. Pediatric vaccination centers often serve as primary sites for administering the recommended vaccine schedule for infants and children, thereby playing a crucial role in ensuring high vaccination rates in these populations. With the increasing focus on child health and preventive care, these centers are expected to see growth in their operations and related services, contributing significantly to the overall demand for pertussis vaccines.

Adult Vaccination Centers:

Adult vaccination centers are becoming increasingly relevant in the context of pertussis vaccination, primarily aimed at educating and administering vaccines to adults. With growing awareness of the need for booster vaccinations, these centers provide an essential service for adults, especially those who are in contact with infants and young children. The emphasis on preventive healthcare and protecting vulnerable populations has led to a rise in the establishment of adult vaccination centers, making them key players in the pertussis vaccine market. By offering convenient access to vaccinations, these centers help to improve public health outcomes and ensure that adults maintain immunity against whooping cough.

By Region

The North American region is anticipated to dominate the Pertussis Vaccine market, accounting for approximately 40% of the global market share. High vaccination rates, robust healthcare infrastructure, and increased awareness of vaccine-preventable diseases contribute to this significant share. The prevalence of pertussis outbreaks in certain areas, along with government initiatives to promote vaccination, has solidified the region's position as a leader in the market. The CAGR for the North American market is estimated at 6.8%, reflecting a steady demand for pertussis vaccines driven by ongoing public health campaigns and educational initiatives.

Europe follows North America closely, with a market share of around 30%. Countries in Europe have established strong vaccination programs, significantly reducing the incidence of whooping cough. However, challenges remain due to vaccine hesitancy in certain populations, which could impact overall vaccination coverage. The European market is projected to grow at a CAGR of 7.1%, fueled by efforts to address vaccine hesitancy through educational programs and outreach initiatives, as well as an increasing focus on maintaining herd immunity.

Opportunities

There are significant opportunities for growth in the Pertussis Vaccine market, particularly in emerging economies where vaccination rates are lower. As these countries invest in healthcare infrastructure and public health initiatives, they present a ripe market for vaccine manufacturers looking to expand their reach. Collaborations between governments and pharmaceutical companies to provide affordable vaccines can lead to increased access and uptake, ultimately reducing the incidence of pertussis in these regions. Furthermore, the potential for innovative vaccine development, including combination vaccines that address multiple illnesses, can create additional market opportunities. With outbreaks of whooping cough still occurring globally, there is an urgent need for vaccination campaigns that can further educate the public and encourage participation in vaccination programs.

Another promising opportunity lies in the development of new technologies for vaccine delivery and administration. The rise of needle-free delivery systems, such as intranasal or microneedle technologies, holds the potential to make vaccination less intimidating, particularly for children and adults who may fear needles. These advancements could improve compliance rates and facilitate easier administration in diverse settings, including non-healthcare environments. Additionally, increasing collaborations among vaccine manufacturers, healthcare providers, and governments can lead to more effective distribution networks and outreach programs, further enhancing vaccination efforts against whooping cough. As public health priorities continue to evolve, the pertussis vaccine market is well-positioned to capitalize on these opportunities and drive growth.

Threats

Despite the positive outlook for the Pertussis Vaccine market, several threats could hinder its growth. One major concern is the emergence of vaccine hesitancy, fueled by misinformation and concerns about vaccine safety. This phenomenon has created challenges for public health campaigns aimed at increasing vaccination rates, particularly in developed regions where access to vaccines is high but acceptance is low. Outbreaks of whooping cough can intensify public concern, but without addressing the root causes of hesitancy, vaccination rates may stagnate or decline. Furthermore, the availability of alternative treatments and the rise of anti-vaccine movements pose significant challenges to the sustained demand for pertussis vaccines, necessitating proactive measures from both healthcare providers and policymakers to counter these trends.

Regulatory challenges present another potential restraining factor in the Pertussis Vaccine market. The approval processes for vaccines can be lengthy and complex, particularly for new formulations or delivery methods. Any delays in regulatory approvals can disrupt the supply chain and hinder timely access to vaccines, especially in regions experiencing outbreaks. Additionally, the need for continual research and development to improve vaccine formulations can strain resources for pharmaceutical companies. The uncertainty surrounding global health events, such as pandemics, may also divert attention and funding away from routine vaccination programs, further complicating efforts to maintain high coverage levels for pertussis vaccines.

Competitor Outlook

• GlaxoSmithKline plc
• Sanofi Pasteur
• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Hybio Pharmaceutical Co., Ltd.
• Serum Institute of India Pvt. Ltd.
• Biological E. Limited
• Vaccine Research Center (VRC)
• Emergent BioSolutions Inc.
• Bharat Biotech International Limited
• Inovio Pharmaceuticals, Inc.
• Seqirus
• Boehringer Ingelheim
• Janssen Pharmaceuticals

The competitive landscape of the Pertussis Vaccine market is characterized by a blend of established pharmaceutical giants and emerging biotech companies. Major players like GlaxoSmithKline, Merck, and Sanofi Pasteur dominate the market, leveraging their extensive distribution networks and strong brand recognition to maintain their positions. These companies are continuously investing in research and development to enhance vaccine efficacy and expand their product portfolios. Additionally, strategic collaborations and partnerships are common among these firms, providing opportunities for sharing resources and expertise in vaccine development. The focus on innovation and the adoption of new technologies, such as combination vaccines and advanced delivery systems, are pivotal in driving competition within the market.

GlaxoSmithKline, for instance, has made significant strides in the pertussis vaccine space with its innovative acellular vaccines, which have gained popularity for their safety and efficacy profiles. The company’s ongoing investment in research aims to improve existing formulations and create new products that meet the evolving needs of public health. Merck & Co., Inc. is another key player, known for its comprehensive vaccination programs and commitment to advancing global health. Their Tdap vaccine has become a cornerstone in preventing whooping cough, especially in adults, demonstrating the importance of addressing all age groups in vaccination efforts.

Sanofi Pasteur has also established a solid foothold in the pertussis vaccine market, focusing on both innovation and accessibility. Their collaboration with government health departments to ensure affordable vaccine distribution has enhanced their reputation as a trusted provider. Furthermore, emerging companies like Bharat Biotech and Biological E. Limited are making significant contributions to the market by developing cost-effective vaccines tailored for developing regions, thus addressing the global challenge of whooping cough outbreaks. The competitive landscape will likely continue evolving as companies adapt to market demands, regulatory challenges, and the need for increased public health awareness.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Seqirus
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi Pasteur
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Merck & Co., Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 GlaxoSmithKline plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Boehringer Ingelheim
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Biological E. Limited
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Janssen Pharmaceuticals
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Emergent BioSolutions Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Inovio Pharmaceuticals, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Vaccine Research Center (VRC)
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hybio Pharmaceutical Co., Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Serum Institute of India Pvt. Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Bharat Biotech International Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Pertussis Vaccine Sales Market, By End User
    • 6.1.1 Pediatric Vaccination Centers
    • 6.1.2 Adult Vaccination Centers
  • 6.2 Pertussis Vaccine Sales Market, By Age Group
    • 6.2.1 Infants
    • 6.2.2 Children
    • 6.2.3 Adults
  • 6.3 Pertussis Vaccine Sales Market, By Product Type
    • 6.3.1 Whole-cell Pertussis Vaccine
    • 6.3.2 Acellular Pertussis Vaccine
  • 6.4 Pertussis Vaccine Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Retail Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Pertussis Vaccine Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Pertussis Vaccine Sales market is categorized based on

By Product Type

• Whole-cell Pertussis Vaccine
• Acellular Pertussis Vaccine

By Age Group

• Infants
• Children
• Adults

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies

By End User

• Pediatric Vaccination Centers
• Adult Vaccination Centers

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• GlaxoSmithKline plc
• Sanofi Pasteur
• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Hybio Pharmaceutical Co., Ltd.
• Serum Institute of India Pvt. Ltd.
• Biological E. Limited
• Vaccine Research Center (VRC)
• Emergent BioSolutions Inc.
• Bharat Biotech International Limited
• Inovio Pharmaceuticals, Inc.
• Seqirus
• Boehringer Ingelheim
• Janssen Pharmaceuticals